NCT06775236View on ClinicalTrials.gov

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

June 15, 2027

Study Completion Date

January 15, 2028

Conditions
Advanced Solid TumorsBreast Cancer
Interventions
DRUG

SYS6010 jnjection

SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker

DRUG

monotherapy chemotherapy

Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)

DRUG

SYH2051 tablets

SYH2051 is a Selective ATM protein kinase inhibitor

All Listed Sponsors
lead

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY